The Latest Cardiac and Vascular News
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu […]
ORLANDO, Fla.–(BUSINESS WIRE)–The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart pumps. The study results were reviewed this morning at Transcatheter Cardiovascular Therapeutics (TCT) 2021, the annual scientific symposium of the Cardiovascular Research Foundation, by Gregg […]
New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO, Fla., Nov. 4, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient […]
— VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition — — VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with VAZALORE 325 mg — — Findings presented at TCT meeting earlier today — SPARTA, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” […]
The NIVA|HF investigational algorithm uses proprietary venous waveform technology from VoluMetrix to assess otherwise hard-to-obtain cardiovascular metrics. According to study authors, ‘This non-invasive measurement has potential for … prevention of hospital admission in heart failure patients.’ NASHVILLE, Tenn., Nov. 04, 2021 (GLOBE NEWSWIRE) — VoluMetrix, a Nashville-based biotech startup dedicated […]
RADIANCE-HTN TRIO and SOLO trial updates demonstrate the durability of blood pressure lowering effects of the Paradise Ultrasound Renal Denervation System in a broad spectrum of patients with hypertension. PALO ALTO, Calif.–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a fully owned subsidiary of Otsuka Holdings Co., Ltd., and […]
LOUISVILLE, CO , Nov. 03, 2021 (GLOBE NEWSWIRE) — Colibri Heart Valve LLC, a privately held emerging medical device company, today announced the initiation of an international pilot study of the Colibri transcatheter aortic valve implantation (TAVI) system. Bernard Chevalier, M.D., an interventional cardiologist at Hôpital Privé Jacques Cartier, is serving […]
Ghent, Belgium – 3 November 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces it has received Medical Device Single Audit Program (MDSAP) certification from its auditing organisation British Standards Institution (BSI), thereby expanding its […]
Study evaluates safety and performance of endovascular pulmonary nerve stimulation in ADHF MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial U.S. enrollment in their global Cardiac Pulmonary Nerve Stimulation (CPNS) Pilot Study (NCT04814134). The study is evaluating the safety and performance of the CPNS System […]
– More than 3 million people in the US have severe hypertriglyceridemia – The CORE Phase 3 clinical study further expands Ionis’ late-stage pipeline and is the second Phase 3 clinical study in Ionis’ broad olezarsen development program – Olezarsen is one of Ionis’ wholly owned medicines the company plans […]
